EP 1244356 A1 20021002 - COMPOSITIONS AND METHODS FOR L-NUCLEOSIDES, L-NUCLEOTIDES, AND THEIR ANALOGS
Title (en)
COMPOSITIONS AND METHODS FOR L-NUCLEOSIDES, L-NUCLEOTIDES, AND THEIR ANALOGS
Title (de)
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR HERSTELLUNG VON L-NUCLEOSIDEN, L-NUCLEOTIDEN UND IHREN ANALOGA
Title (fr)
COMPOSITIONS ET PROCEDES RELATIVES A DES NUCLEOSIDES-L, A DES NUCLEOTIDES-L AINSI QU'A LEURS ANALOGUES
Publication
Application
Priority
- US 0034605 W 20001219
- US 17209799 P 19991223
- US 17344699 P 19991229
- US 17511100 P 20000106
- US 19075800 P 20000320
- US 22694700 P 20000822
- US 22687500 P 20000822
- US 23382100 P 20000919
- US 23382300 P 20000919
- US 23354800 P 20000919
- US 23382200 P 20000919
- US 23546500 P 20000926
Abstract (en)
[origin: WO0145509A1] Nucleoside and nucleotide compounds and their analogs/prodrugs are provided. Particularly contemplated compounds include 1- beta -L-ribofuranosyl-1,2,4-triazole-3-carboxamide, which may be modified and/or phosphorylated. Contemplated compounds may further be combined with other pharmacological compounds, especially including Ribavirin, antibodies, and cytokines. Preferred uses of contemplated compounds include use as an antiviral compound, anti-inflammatory compound, antineoplastic compound, and as a compound to stimulate cellular growth.
IPC 1-7
IPC 8 full level
A01N 43/72 (2006.01); A61K 31/70 (2006.01); A61K 31/7056 (2006.01); A61K 38/21 (2006.01); A61K 39/395 (2006.01); C07H 19/056 (2006.01); A61K 45/00 (2006.01); A61P 1/16 (2006.01); A61P 25/00 (2006.01); A61P 31/12 (2006.01); A61P 31/16 (2006.01); A61P 31/18 (2006.01); A61P 37/02 (2006.01); A61P 43/00 (2006.01); C07H 19/12 (2006.01)
IPC 8 main group level
A61P 29/00 (2006.01); A61P 35/00 (2006.01)
CPC (source: EP KR)
A01N 43/72 (2013.01 - EP); A61K 31/70 (2013.01 - EP); A61K 31/7056 (2013.01 - EP); A61K 39/395 (2013.01 - EP); A61P 1/16 (2018.01 - EP); A61P 25/00 (2018.01 - EP); A61P 29/00 (2018.01 - EP); A61P 31/12 (2018.01 - EP); A61P 31/16 (2018.01 - EP); A61P 31/18 (2018.01 - EP); A61P 35/00 (2018.01 - EP); A61P 37/02 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C07H 19/056 (2013.01 - KR); C07H 19/12 (2013.01 - EP)
C-Set (source: EP)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0145509 A1 20010628; AU 2442201 A 20010703; BR 0016162 A 20020813; CA 2384326 A1 20010628; CN 1420723 A 20030528; CZ 20022112 A3 20030514; EP 1244356 A1 20021002; EP 1244356 A4 20030319; HK 1049944 A1 20030606; HR P20020485 A2 20051031; HU P0300219 A2 20030628; HU P0300219 A3 20050728; IL 148514 A0 20020912; JP 2003523957 A 20030812; KR 20030032908 A 20030426; MX PA02006251 A 20030128; NO 20022969 D0 20020620; NO 20022969 L 20020620; NZ 517634 A 20040625; PL 364927 A1 20041227; SI 20976 A 20030228; SK 8612002 A3 20030304; YU 47802 A 20060303
DOCDB simple family (application)
US 0034605 W 20001219; AU 2442201 A 20001218; BR 0016162 A 20001219; CA 2384326 A 20001219; CN 00817416 A 20001219; CZ 20022112 A 20001219; EP 00988189 A 20001219; HK 03102255 A 20030328; HR P20020485 A 20020603; HU P0300219 A 20001219; IL 14851400 A 20001219; JP 2001546256 A 20001219; KR 20027008069 A 20020621; MX PA02006251 A 20001219; NO 20022969 A 20020620; NZ 51763400 A 20001219; PL 36492700 A 20001219; SI 200020047 A 20001219; SK 8612002 A 20001219; YU P47802 A 20001219